CCG-143140

Research use only, not for human use.

CCG-143140 is a GLP-1 receptor inverse agonists.

CCG-143140 is a GLP-1 receptor inverse agonists.

ML-SI3 (10 μM) inhibits ML-SA1-evoked Ca2+ signals in HeLa cells.ML-SI3 (25-75 μM, 24h) disrupts tegumental integrity of adult schistosomes.ML-SI3 (10 μM) blocks Rapamycin (HY-10219)-evoked ITRPML1 in mimic of lysosomal lumen.ML-SI3 (3 μM, 6 h) abolishes the increase in both LC3II and p62 levels induced by hypoxia/reoxygenation (H/R) (4 h H/2 h R) in neonatal rat ventricular myocytes (NRVM).

ML-SI3 (1.5 mg/kg, i.p., four times) attenuates I/R injury in mouse cardiomyocytes. Animal Model:Myocardial Ischemia/reperfusion (I/R) injury miceDosage:1.5 mg/kg Administration:Intraperitoneal injection (i.p.), four times before and during the in vivo I/R (ischemia 30 min and reperfusion 1 day)Result:Restored the blocked autophagic fux in the cardiomyocytes subjected to I/R.

ML-SI3

GPCR/G Protein

Glucagon Receptor

GLP-1

——

——

891016-02-7

429.58

C23H31N3O3S

>98% (HPLC)

In Vitro:?DMSO : 50 mg/mL (116.39 mM)

O=S(C1=CC=CC=C1)(NC2C(N3CCN(C4=CC=CC=C4OC)CC3)CCCC2)=O

——

(-20℃)

With Ice Pack

≥ 2 years